drugset / Trial / NCT00835185

Study of IMC-11F8 in Participants With Colorectal Cancer

NCT00835185

Phase 2 Completed 44 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if IMC-11F8 in combination with chemotherapy is effective in treating colorectal cancer (CRC).

Timeline

Start
2007-08
Primary completion
2010-01
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Necitumumab Monoclonal antibody 800 mg Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications